Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
(2016) In Respiratory Research 17(1).- Abstract
Background: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease and those who have not previously received maintenance therapy are of interest. OTEMTO® 1 and 2 were two replicate, 12-week, Phase III studies investigating the benefit of tiotropium + olodaterol on lung function and quality of life in patients with moderate to severe disease. Post hoc analyses were performed to assess the benefits for patients according to disease severity and treatment history. Methods: Four subgroup analyses were performed: Global initiative for chronic Obstructive Lung Disease (GOLD) 2/3, GOLD A/B/C/D, treatment naive/not treatment naive... (More)
Background: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease and those who have not previously received maintenance therapy are of interest. OTEMTO® 1 and 2 were two replicate, 12-week, Phase III studies investigating the benefit of tiotropium + olodaterol on lung function and quality of life in patients with moderate to severe disease. Post hoc analyses were performed to assess the benefits for patients according to disease severity and treatment history. Methods: Four subgroup analyses were performed: Global initiative for chronic Obstructive Lung Disease (GOLD) 2/3, GOLD A/B/C/D, treatment naive/not treatment naive and receiving inhaled corticosteroids (ICS) at baseline/not receiving ICS at baseline. Primary end points were change in forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h response, change in trough FEV1 and St George's Respiratory Questionnaire (SGRQ) total score. Transition Dyspnoea Index (TDI) focal score was a secondary end point, and SGRQ and TDI responder analyses were further end points; all were assessed at 12 weeks. Results: In all subgroups, patients receiving tiotropium + olodaterol responded better overall than those receiving tiotropium monotherapy. Improvements with tiotropium + olodaterol over placebo or tiotropium monotherapy were noted across GOLD 2/3 and GOLD A/B/C/D; however, improvements in SGRQ total score were most evident in the GOLD B subgroup. Moreover, lung-function outcomes were generally greater in those patients who had been receiving previous long-acting bronchodilator and/or ICS maintenance treatment. Conclusions: These data suggest that tiotropium + olodaterol should be considered as a treatment option in patients with moderate COPD who are initiating maintenance therapy, as well as those with more severe disease. Trial registration: ClinicalTrials.gov: NCT01964352and NCT02006732.
(Less)
- author
- Singh, Dave ; Gaga, Mina ; Schmidt, Olaf ; Bjermer, Leif LU ; Grönke, Lars ; Voß, Florian and Ferguson, Gary T.
- organization
- publishing date
- 2016-06-18
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COPD, Long-acting bronchodilator, Olodaterol, Severity, Tiotropium, Treatment history
- in
- Respiratory Research
- volume
- 17
- issue
- 1
- article number
- 73
- publisher
- BioMed Central (BMC)
- external identifiers
-
- scopus:84975282827
- pmid:27316465
- wos:000377973900001
- ISSN
- 1465-9921
- DOI
- 10.1186/s12931-016-0387-7
- language
- English
- LU publication?
- yes
- id
- 280dd4b9-f5da-4a03-a5b0-c6f412ac1462
- date added to LUP
- 2016-07-11 12:31:36
- date last changed
- 2024-04-19 06:00:27
@article{280dd4b9-f5da-4a03-a5b0-c6f412ac1462,
abstract = {{<p>Background: As lung function declines rapidly in the early stages of chronic obstructive pulmonary disease (COPD), the effects of bronchodilators in patients with moderate disease and those who have not previously received maintenance therapy are of interest. OTEMTO® 1 and 2 were two replicate, 12-week, Phase III studies investigating the benefit of tiotropium + olodaterol on lung function and quality of life in patients with moderate to severe disease. Post hoc analyses were performed to assess the benefits for patients according to disease severity and treatment history. Methods: Four subgroup analyses were performed: Global initiative for chronic Obstructive Lung Disease (GOLD) 2/3, GOLD A/B/C/D, treatment naive/not treatment naive and receiving inhaled corticosteroids (ICS) at baseline/not receiving ICS at baseline. Primary end points were change in forced expiratory volume in 1 s (FEV<sub>1</sub>) area under the curve from 0 to 3 h response, change in trough FEV<sub>1</sub> and St George's Respiratory Questionnaire (SGRQ) total score. Transition Dyspnoea Index (TDI) focal score was a secondary end point, and SGRQ and TDI responder analyses were further end points; all were assessed at 12 weeks. Results: In all subgroups, patients receiving tiotropium + olodaterol responded better overall than those receiving tiotropium monotherapy. Improvements with tiotropium + olodaterol over placebo or tiotropium monotherapy were noted across GOLD 2/3 and GOLD A/B/C/D; however, improvements in SGRQ total score were most evident in the GOLD B subgroup. Moreover, lung-function outcomes were generally greater in those patients who had been receiving previous long-acting bronchodilator and/or ICS maintenance treatment. Conclusions: These data suggest that tiotropium + olodaterol should be considered as a treatment option in patients with moderate COPD who are initiating maintenance therapy, as well as those with more severe disease. Trial registration: ClinicalTrials.gov: NCT01964352and NCT02006732.</p>}},
author = {{Singh, Dave and Gaga, Mina and Schmidt, Olaf and Bjermer, Leif and Grönke, Lars and Voß, Florian and Ferguson, Gary T.}},
issn = {{1465-9921}},
keywords = {{COPD; Long-acting bronchodilator; Olodaterol; Severity; Tiotropium; Treatment history}},
language = {{eng}},
month = {{06}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{Respiratory Research}},
title = {{Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies}},
url = {{http://dx.doi.org/10.1186/s12931-016-0387-7}},
doi = {{10.1186/s12931-016-0387-7}},
volume = {{17}},
year = {{2016}},
}